Molecular Insights into Cancer Invasion: Strategies for Prevention and Intervention

Cancer Research

Volumn 55, Issue 9, 1995, Pages 1856-1862

  Kohn, Elise C ^a   Liotta, Lance A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; BATIMASTAT; CYTOSTATIC AGENT; METALLOPROTEINASE INHIBITOR; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANGIOGENESIS; CALCIUM HOMEOSTASIS; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PREVENTION; HUMAN; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

AMINO ACID SEQUENCE; ANIMAL; ANTICARCINOGENIC AGENTS; CARCINOMA IN SITU; HUMAN; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0028944106     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. Astrow, A. B. Commentary: rethinking cancer. Lancet, 343: 494–495, 1994.
2. Bailar, J. C., and Smith, E. Progress against cancer? N. Engl. J. Med., 314: 1226–1232, 1986.
3. Gallager, H. S., and Martin, J. E. The study of mammary carcinoma by mammography and whole organ sectioning, early observations, Cancer (Phila.), 23: 855–866, 1969.
4. Kelloff, G. J., Boone, C. W., Steele, V., et al. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res., 54: 2015–2024, 1994.
5. Spratt, J. S., Greenberg, R. A., and Heuser, L. S. Geometry, growth rates, and duration of cancer and carcinoma in situ of the breast before detection by screening. Cancer Res., 46: 970–974, 1986.
6. Wattenberg, L. W. Prevention therapy: basic science and the resolution of the cancer problem—presidential address. Cancer Res., 53: 5890–5896, 1993.
7. Zhuang, Z., Merino, M., Chuaqui, R., Liotta, L. A., and Emmert-Buck, M. Identical allelic loss on chromosome 1lql3 in microdissected in situ and invasive human breast cancer. Cancer Res., 55: 467–471, 1995.
8. Bedwani, R., Vana, J., Rosner, D., et al. Management and survival of female patients with minimal breast cancer. Cancer (Phila.), 47: 2769–2778, 1981.
9. Melamed, M. Circulating cancer cells. In: L. G. Koss (ed.), Diagnostic Cytology and Its Histopathologic Bases, Ed. 4, Vol. 2, pp, 1403–1419. Philadelphia: J. B. Lippincott Company, 1992.
10. Liotta, L. A., Kleinerman, J., and Saidel, G. Quantitative relationships of intravascular tumor cells: tumor vessels and pulmonary metastases following tumor implantation. Cancer Res., 34: 997–1003, 1974.
11. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182–1186, 1971.
12. Nicolson, G. L. Gene expression, cellular diversification and tumor progression to the metastatic phenotype. Bioessays, 13: 337–342, 1991.
13. Liotta, L. A., Tryggvason, K., Garbisa, S., Gehron-Robey, P., and Abe, S. Partial purification and characterization of a neutral proteinase which cleaves type IV collagen. Biochemistry, 20: 100–104, 1981.
14. Barsky, S. H., Siegal, G. P., Jannotta, F., and Liotta L. A. Loss of basement membrane components by invasive tumors but not by their benign counterparts, Lab. Invest., 49: 140–147, 1983.
15. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61: 759–767, 1990.
16. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis; an imbalance of positive and negative regulation. Cell, 64: 327–336, 1991.
17. Hynes, R. O., and Lander, A. D. Contact and adhesive specificities in the associations, migrations, and targeting of cells and axons. Cell, 68: 303–322, 1992.
18. Seftor, R. E. B., Seftor, E. A., Genisen, K. R., Stetler-Stevenson, W. G., Ruoslahti, E., and Hendrix, M. J. C. Role of the avβ3 integrin in human melanoma cell invasion. Proc. Natl. Acad. Sci. USA, 89: 1557–1561, 1992.
19. Frixen, U. H., Behrens, J., Sachs, M., et al. E-cadherin-mediated cell-cell adhesion prevents invasivenss of human colorectal carcinoma cells. J. Cell Biol., 113: 173–185, 1991.
20. Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., and Shafie, S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (Lond.), 284: 67–68, 1980.
21. Rong, S., Segal, S., Anver, M., Resau, J. H., and Vande Woude, G. F. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Natl. Acad. Sci. USA, 91: 4731–4735, 1994.
22. Stracke, M. L., Krutzsch, H. C., Unsworth, E. J., årestad, A., Cioce, V., Schiffinann, E., and Liotta, L. A. Identification, purification, and partial sequence analysis of autotaxin, a novel nrotffity-stimulating protein. J. Biol. Chem., 267: 2524–2529, 1992.
23. Powis, G. Signaling targets for anticancer drug development. Trends Pharmacol. Sci., 12: 188–194, 1991.
24. Irvine, R. F. Inositol phosphates and Ca2+ entry: toward a proliferation or a simplification, FASEB J., 6: 3085–3091, 1992.
25. Gibbs, J. B., Oliff, A., and Kohl, N. E. Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell, 77: 175–178, 1994.
26. Cole, K. A., and Kohn, E. C. Calcium-mediated signal transduction: biology, biochemistry, and therapy. Cancer Metastasis Rev., 13: 33–41, 1994.
27. Bendeck, M. P., Zempo, N., Clowes, A. W., and Reidy, M. A. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res., 75: 539–545, 1994.
28. Weidner, N. Tumor angiogenesis: reveiw of current applications in tumor prognostication. Scmin. Diagn. Pathol., 10: 302–313, 1993.
29. Talhouk, R. S., Bisell, M. J., and Werb, Z. Coordinated expression of extracellular matrix degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J. Cell Biol., 118: 1271–1282, 1992.
30. Wu, D.-Y., and Goldberg, D. J. Regulated tyrosine phosphorylation at the tips of growth cone filopodia. J. Cell Biol., 123: 653–664, 1993.
31. Lola, P. K., and Graham, C. H. Mechanisms of trophoblast invasiveness and their control: the role of proteases and protease inhibitors. Cancer Metastasis Rev., 9: 369–380, 1990.
32. Schirrmacher, V. Cancer Metastasis: experimental approaches, theoretical concepts, and impacts for treatment strategies. Adv. Cancer Res., 43: 1–73, 1985.
33. Condeelis, J. Life at the leading edge: the formation of cell protrusions. Annu. Rev. Physiol., 9: 411–444, 1993.
34. Stossel, T. P. On the crawling of animal cells. Science (Washington DC), 260: 1086–1094, 1993.
35. Guirguis, R., Margulies, I., Taraboletti, G., and Liotta, L. Cytokine-induced pseudopodial protrusion is coupled to tumour cell migration. Nature (Lond.), 329: 261–263, 1987.
36. Dong, C., Aznavoorian, S., and Liotta, L. A. Two phases of pseudopod protrusion in tumor cells revealed by a micropipette. Microvasc. Res., 47: 55–67, 1994.
37. Damsky, C. H., and Werb, Z. Signal transduction by integrin receptors for extracellular matrix: cooperation and processing of extracellular information. Curr. Opin. Cell Biol., 4: 772–781, 1992.
38. Blasi, F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays, 15: 105–111, 1993.
39. Sato, H., Takino, T., Yasunori, O., Cao, J., Shinagawa, E. Y., and Seiki, M. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature (Lond.), 370: 61–65, 1994.
40. Sato, H., Kita, M., and Seiki, M. v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. J. Biol. Chem., 268: 23460–23468, 1993.
41. Axelrod, J. H., Reich, R., and Mishkin, R. Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells. Mol. Cell. Biol., 9: 2133–2141, 1989.
42. Rochefort, H., Capony, F., and Garcia, M. Cathepsin D: a protease involved in breast cancer metastasis. Cancer Metastasis Rev., 9: 321–331, 1990.
43. Witty, J. P., Mcdonnell, S., Newell, K. J., Cannon, P., Navre, M., Tressler, R. J., and Matrisian, L. M. Modulation of matri lysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res., 54: 4805–4812, 1994.
44. Tempieton, N. S., Brown, P. D., Levy, A. T., Margulies, I. M. K., Liotta, L. A., and Stetler-Stevenson, W. G. Cloning and characterization of human tumor cell interstitial collagenase. Cancer Res., 50: 5431–5437, 1990.
45. Nakajima, M., Morikawa, K., Fabra, A., et al. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J. Natl. Cancer Inst., 82: 1890–1898, 1990.
46. Mignatti, P., Robbins, E., and Rifkin, D. B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell, 47: 487–498, 1986.
47. Thorgeirsson, U. P., Liotta, L. A., Kalebic, T., et al. Effect of the natural protease inhibitors and a chemoattractant on tumor invasion in vitro. J. Natl. Cancer Inst., 69: 1049–1054, 1982.
48. Matrisian, L. M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet., 6: 121–125, 1990.
49. Wilhelm, S. M., Collier, I. E., Marmer, B. L., et al. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem., 264: 17213–17221, 1989.
50. Fessler, L., Duncan, K., and Tryggvason, K. Identification of the procollagen IV cleavage products produced by a specific tumor collagenase. J. Biol. Chem., 259: 9783–9789, 1984.
51. Stetler-Stevenson, W. G., Krutzsch, H. C., and Liotta, L. A. Tissue inhibitor of metalloproteinase (TIMP-2): a new member of the metalloproteinase inhibitor family. J. Biol. Chem., 264: 17374–17378, 1989.
52. Goldberg, G. I., Marmer, B. L., Grant, G. A., et al. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteinases designated TIMP-2. Proc. Natl. Acad. Sci. USA, 86: 8207–8211, 1989.
53. DeClerck, Y. A., Yean, T. D., Ratzkin, B. J., et al. Purification and characterization of two related but distinct metalloproteinase inhibitors secreted by bovine aortic endothelial cells. J. Biol. Chem., 264: 17445–17453, 1989.
54. Murphy, G., Cawston, T., and Reynolds, J. An inhibitor of collagenase from human amniotic fluid: purification, characterization, and action on metalloproteinases. Biochem. J., 195: 167–173, 1981.
55. Howard, E. W., Bullen, E. C., and Banda, M. J. Preferential inhibition of 72 kDa and 92 kDa gelatinases by TIMP-2. J. Biol. Chem., 266: 13070–13075, 1991.
56. Ura, H., Bonfil, R. D., Reich, R., et al. Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive and metastatic abilities of oncogene-transformed human bronchial epithelial cells. Cancer Res., 49: 4615–4622, 1989.
57. Monteagudo, C., Merino, M., San Juan, J., et al. Immunohistologic distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am. J. Pathol., 136: 585–592, 1990.
58. Levy, A., Cioce, V., Sobel, M. E., et al. Increased expression of the 72 kDa type IV collagenase in human colonic adenocarcinoma. Cancer Res., 51: 439–444, 1991.
59. Schultz, R. M., Silberman, S., Persky, B., et al. Inhibition by recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16 F10 melanoma cells. Cancer Res., 48: 5539–5545, 1988.
60. Khokha, R., Waterhouse, P., Yagel, S., et al. Antisense RNA-induced reduction in murine TIMP level confers oncogenicity on Swiss 3T3. Science (Washington DC), 243: 947–950, 1989.
61. Albini, A., Melchiori, A., Santi, L., et al. Tumor cell invasion inhibited by TIMP-2. J. Natl. Cancer Inst., 83: 775–779, 1991.
62. DeClerck, Y. A., Perez, N., Shimada, H., et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res., 52: 701–708, 1992.
63. Mignatti, P., Tsuboi, R., Robbins, E., and Rifkin, D. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J. Cell Biol., 108: 671–682, 1989.
64. Schwartz, M. A., and Van Wart, H. E. Eight synthetic inhibitors of bacterial and mammalian interstitial collagenases. Prog. Med. Chem., 29: 271–334, 1992.
65. Stetler-Stevenson, W. G., Krutzsch, H. C., Wacher, M. P., Margulies, I. M. K., and Liotta, L. A. The activation of human type IV collagenase proenzyme. Sequence identification of the major converstion product following orangomercurial activation. J. Biol. Chem., 264: 1353–1356, 1989.
66. Melchiori, A., Albini, A., Ray, J. M., et al Inhibition of tumor cell invasion by a highly conserved peptide sequence form the matrix metalloproteinase enzyme pro-segment. Cancer Res., 52: 2353–2356, 1992.
67. Fotouhi, N., Lugo, A., Visnick, M., Lusch, L., Walsky, R., Coffey, J. W., and Hanglow, A. C. Potent peptide inhibitors of stromelysin based on the prodomain region of matrix metalloproteinases. J. Biol. Chem., 269: 30227–30231, 1994.
68. Wang, X., Fu, X., Brown, P. D., Crimmin, M. J., and Hoffman, R. M. Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res., 54: 4726–472S, 1994.
69. Sheffield, J. B., Krasnopolsky, V., and Dehlinger, E. Inhibition of retinal growth cone activity by specific metalloproeinase inhibitors in vitro. Dev., Dynamics, 200: 79–88, 1994.
70. Galardy, R., Grobelney, D., Foellmer, H. G., and Fernandez, L. A. Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R-2-(hydroxamidocar-bonymethyl)-4-methylpentanoyl)]-L-tryptophan methylamide. Cancer Res., 54: 4715–4718, 1994.
71. Davies, B., Brown, P. D., East, N., Criinmin, M. J., and Balkwill, F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res., 53: 2087–2091, 1993.
72. Yarden, Y., and Urlich, A. Growth factor receptor kinases. Annu. Rev. Biochem., 57: 443–478, 1988.
73. Sato, H., and Seiki, M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cell. Oncogene, 8: 385–405, 1993.
74. Prendergast, G. C., Davide, J. P., Krai, A., Diehl, R., Gibbs, J. B., Omer, C. A., and Kohl, N. E. Negative growth selection against rodent fibroblasts targeted for genetic inhibition of farnesyl transferase. Cell Growth & Differ., 4: 707–713, 1993.
75. Powis, G. Drugs active against growth factor and oncogene phosphatidylinositol signaling pathways. Semin. Cancer Biol., 3: 343–350, 1992.
76. Schwartz, G. K., Jiang, J., Kelsen, D., and Albino, A. P. Protein kinase C: a novel target for inhibiting gastric cancer invasion. J. Natl. Cancer Inst, 85: 402–407, 1993.
77. Kerr, L. D., Miller, D. B., and Matrisian, L. M. TGF-βl inhibition of transin/stromelysin gene expression is mediated through a fos binding sequence. Cell, 61: 267–278, 1990.
78. Kohn, E. C., and Liotta, L. A. L651582, a novel antiproliferative and antimetastasis agent. J. Natl. Cancer Inst., 82: 54–60, 1990.
79. Kohn, E. C., Sandeen, M. A., and Liotta, L. A. In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res., 52: 3208–3212, 1992.
80. Kohn, E. C., Jacobs, W., Kim, Y. S., Alessandro, R., Stetler-Stevenson, W. G., and Liotta, L. A. Calcium influx regulates matrix metalloproteinase-2 (72 kDa type IV collagenase, gelatinase A) expression. J. Biol. Chem., 269: 21505–21511, 1994.
81. Kohn, E. C., Felder, C. C., Jacobs, W., Holmes, K. A., Day, A., Freer, R., and Liotta, L. A. Stucture-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI. Cancer Res., 54: 935–942, 1994.
82. Kohn, E. C., Alessandro, R., Spoonster, J., Wersto, R. W., and Liotta, L. A. Angiogenesis: role of calcium-mediated signal transduction. Proc. Natl. Acad. Sci. USA, 92: 1307–1311, 1995.
83. Gusovsky, F., Lueders, J. E., Kohn, E. C., and Felder, C. C. Muscarinic receptor-mediated tyrosine phosphorylation of phospholipase C-y: an alternative mechanism for cholinergic-induced phosphoinositide breakdown. J. Biol. Chem., 268: 7768–7772, 1993.
84. Felder, C. C., Ma, A. L., Liotta, L. A., and Kohn, E. C. The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J. Pharmacol. Exp. Ther., 257: 967–971, 1991.
85. Chapron, Y., Cochet, C., Crouzy, S., Jullien, T., Keramidas, M., and Verdetti, J. Tyrosine protein kinase activity of the EGF receptor is required to induce activation of receptor-operated calcium channels. Biochem. Biophys. Res. Commun., 158: 527–533, 1989.
86. Janney, P. A. Phosphoinositides and calcium as regulators of cellular actin assembly and disassembly. Annu. Rev. Physiol., 56: 169–191, 1994.
87. Meldolesi, J., Clementi, E., Fusolato, C., Zacchetti, D., and Pozzan, T. Ca2+ influx following receptor activation. Trends Pharmacol. Sci., 12: 289–292, 1991.
88. Prendergast, G. C., and Gibbs, J. B. Pathways of ras function: connections to the actin cytoskeleton. Adv. Cancer Res., 62: 19–64, 1993.
89. Pozzatti, R., Muschel, R., Williams, J., Padmanabhan, R., Howard, B., Liotta, L., and Khoury, G. Primary rat embryo cells transformed by one or two oncogenes show different metastatic potentials. Science (Washington DC), 232: 223–227, 1986.
90. Yu, D., Shi, D., Scanlon, M., and Hung, M. C. Reexpression of røi-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A. Cancer Res., 53: 5784–5790, 1993.
91. Tanaguchi, T., Kitagawea, H., Yasue, S., et al. Protein-tyrosine kinase p72syk is activated by thrombin and is negatively regulated through Cpa2+ regulation in platelets. J. Biol. Chem., 268: 2277–2279, 1993.
92. Savarese, D. M. F., Russell, J. T., Fatatis, A., and Liotta, L. A. Type IV collagen stimulates an increase in intracellular calcium: potential role in tumor cell motility. J. Biol. Chem., 267: 21928–21935, 1992.